reports
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; November 21, 2024 – (Nasdaq: GMAB) announced today that the Board decided to grant 10,273 restricted stock units and 10,853 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 1,447.50...
Carlsberg AS: 1 director
A director at Carlsberg AS bought 4,000 shares at 717.743DKK and the significance rating of the trade was 88/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Atrium Ljungberg AB: 1 director
A director at Atrium Ljungberg AB bought 4,921 shares at 203.000SEK and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
- Patrik Ling
Alvotech (Buy, TP: USD21.00) - Yet another strong quarter
Despite another profitable quarter, the YTD performance and Q4 outlook comments, Alvotech reiterated its full-year sales guidance with the Q3 results, which seems slightly conservative to us. The pipeline is evolving as expected, and we believe several new products should reach the market in the coming years, with the biosimilar to Stelara slated for a US launch in late February. We reiterate our BUY and USD21 target price.
Transactions in connection with share buyback programme
Transactions in connection with share buyback programme Company Announcement Copenhagen, 18 November 2024 No. 58/2024 Transactions in connection with share buyback programmeISS A/S, a leading workplace experience and facility management company, announced on 22 February 2024 a new share buyback programme, see company announcement no. 4/2024. The share buyback programme is executed in accordance Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, al...
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Markus Henriksson
- Oscar Lindquist
HUFV A HUFVUDSTADEN AB CLASS A
OLT OLAV THON EIENDOMSSELSKAP ASA
CAST CASTELLUM AB
CATE CATENA AB
DIOS DIOS FASTIGHETER AB
EAST EASTNINE AB
ATRLJ B ATRIUM LJUNGBERG AB CLASS B
A1W9VK PLATZER FASTIGHETER HOLDING AB CLASS B
ENTRA ENTRA ASA
STEF B STENDOERREN FASTIGHETER AB CLASS B
POX PANDOX AB CLASS B
A1T7SE AB SAGAX CLASS B
SBB B SAMHALLSBYGGNADSBOLAGET I NORDEN AB CLASS B
FABG FABEGE AB
NYF NYFOSA AB
FAST A FASTPARTNER AB
K2A B K2A KNAUST & ANDERSSON FASTIGHETER AB
KLARA B KLARABO SVERIGE AB
WIHL WIHLBORG FASTIGHETER AB(PUBL)
BALD B FASTIGHETS AB BALDER
WALL B WALLENSTAM AB
SLP B SWEDISH LOGISTIC PROPERTY AB
PUBLI PUBLIC PROPERTY INVEST
- ABGSC Food & Beverage Research
- Peter Sehested
- Jesper Ingildsen
Royal Unibrew (Buy, TP: DKK675.00) - Strong Q3, as expected
Royal Unibrew reported largely in line with our forecasts when adjusted for a positive one-off, with c27% organic EBIT growth, driven by a solid performance across all regions. As expected, based on YTD performance and tough comparables in Q4, the company narrowed its 2024 organic EBIT growth guidance from 14–19% to 15–19% YOY (consensus c17%). We reiterate our BUY and DKK675 target price.
- ABGSC Food & Beverage Research
- Peter Sehested
Q3 2024 Trading Statement - Strong earnings improvement and EBIT margi...
Q3 2024 Trading Statement - Strong earnings improvement and EBIT margin expansion Company Announcement No 18/2024 – November 12, 2024 Key highlights in Q3 2024 Organic volume growth 8% in Q3. Total volume growth of 35%Organic net revenue increased by 8% to DKK 4,083m in Q3. Total revenue growth of 22%Market shares were gained or maintained in most countriesOrganic EBIT growth 25%. EBIT from acquisitions DKK 41m in Q3. Total EBIT growth 33%EBIT margin increased to 16.5% in Q3 (Q3 2023: 15.2%)PepsiCo’s beverage business in Belgium and Luxembourg was transferred to Royal Unibrew on ...
Transactions in connection with share buyback programme
Transactions in connection with share buyback programme Company Announcement Copenhagen, 11 November 2024 No. 57/2024 Transactions in connection with share buyback programmeISS A/S, a leading workplace experience and facility management company, announced on 22 February 2024 a new share buyback programme, see company announcement no. 4/2024. The share buyback programme is executed in accordance Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/...
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Markus Henriksson
- Oscar Lindquist
HUFV A HUFVUDSTADEN AB CLASS A
OLT OLAV THON EIENDOMSSELSKAP ASA
CAST CASTELLUM AB
CATE CATENA AB
DIOS DIOS FASTIGHETER AB
EAST EASTNINE AB
ATRLJ B ATRIUM LJUNGBERG AB CLASS B
A1W9VK PLATZER FASTIGHETER HOLDING AB CLASS B
ENTRA ENTRA ASA
STEF B STENDOERREN FASTIGHETER AB CLASS B
POX PANDOX AB CLASS B
A1T7SE AB SAGAX CLASS B
SBB B SAMHALLSBYGGNADSBOLAGET I NORDEN AB CLASS B
FABG FABEGE AB
NYF NYFOSA AB
FAST A FASTPARTNER AB
K2A B K2A KNAUST & ANDERSSON FASTIGHETER AB
KLARA B KLARABO SVERIGE AB
WIHL WIHLBORG FASTIGHETER AB(PUBL)
BALD B FASTIGHETS AB BALDER
WALL B WALLENSTAM AB
SLP B SWEDISH LOGISTIC PROPERTY AB
PUBLI PUBLIC PROPERTY INVEST
- Simen Mortensen
Mixed Q3s and soft datapoint for Stockholm office market
This week, Hufvudstaden, Veidekke, Selvaag Bolig and Skanska reported Q3 results. Furthermore, Vasakronan (unlisted) reported soft vacancies and net lettings, which we consider a negative datapoint for peers such as Fabege and Hufuvdstaden. The weighted-average implied EBITDA yields on the stocks we cover are 4.33% for 2024e and 4.88% for 2025e.
OLT OLAV THON EIENDOMSSELSKAP ASA
BALD B FASTIGHETS AB BALDER CLASS B
CAST CASTELLUM AB
CATE CATENA AB
WALL B WALLENSTAM AB CLASS B
ATRLJ B ATRIUM LJUNGBERG AB CLASS B
KMCP KMC PROPERTIES
ENTRA ENTRA ASA
POX PANDOX AB CLASS B
SBB B SAMHALLSBYGGNADSBOLAGET I NORDEN AB CLASS B
FABG FABEGE AB
WIHL WIHLBORGS FASTIGHETER AB
CORE B COREM PROPERTY GROUP (B)
KOJAMO KOJAMO OYJ
CTY1S CITYCON OYJ
NYF NYFOSA AB
SAGAB SAGAX
AURA AURORA EIENDOM
PUBLI PUBLIC PROPERTY INVEST
- ABGSC Capital Goods Research
- Karl Bokvist
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Rune Majlund Dahl
Genmab (Buy, TP: DKK2500.00) - Still awaiting CD-38 decision
Q3 revenue missed our expectations, but operating profit exceeded due to lower operating costs. 2024 guidance for revenue was raised to DKK21.1bn–21.7bn; for opex was narrowed downwards to DKK14.1bn–14.4bn (due to portfolio prioritisation); and for operating profit, narrowed to the high end of DKK6.2bn–7.1bn. Investor focus was on JNJ’s upcoming opt-in decision (data submission expected end-2024). We reiterate our BUY and DKK2,500 target price.
- ABGSC Services Research
- Peter Sehested
Genmab Announces Financial Results for the First Nine Months of 2024
Genmab Announces Financial Results for the First Nine Months of 2024 November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapyGenmab announced that it will assume sole responsibility for the continued development and potential commercialization of acasunlimabGenmab revenue increased 29% com...
- Mads Brinkmann Andersen
ISS (Buy, TP: DKK171.00) - New wins still key question mark
ISS reported a somewhat uneventful Q3, with a c3% miss versus consensus on the reported top line, mainly on greater-than-expected FX headwinds. Organic growth was a bit soft, but with negative and positive surprises in the form of weaker underlying portfolio volumes but better-than-feared above-base volumes. We reiterate our BUY and DKK171 target price.
Genmab to Present at Jefferies London Healthcare Conference
Genmab to Present at Jefferies London Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; November 5, 2024 (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van de Winkel, Ph.D. and Chief Financial Officer, Anthony Pagano will take part in a fireside chat at the Jefferies London Healthcare Conference on November 19, 2024 at 4:30 PM CET / 10:30 AM EST. A webcast of the event will be available on Genmab’s website at . About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.